Age-specific risk of herpes zoster in immunocompetent adults ≥18 years-of-age – a retrospective cohort study in the United States
Rachel A Cohen·Huifeng Yun·Bruno Anspach·Driss Oraichi·Desmond Curran·Agnes Mwakingwe-Omari·Mitra Yousefi
Abstract Background Approximately one-third of United States (US) individuals develop herpes zoster (HZ). Recent HZ incidence data are lacking, especially in immunocompetent adults 18–49 years-of-age (YoA). Recombinant HZ vaccine is recommended for US adults ≥50YoA and immunocompromised/immunosuppressed adults ≥19YoA. Methods This retrospective cohort study (2015–2022, Merative MarketScan Commercial/Medicare) estimated age-specific HZ burden and incidence rates (IR) per 1000 person-years in immu